patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_660636 | REC_0007901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.2 | 59 | female | 1 | 13 | 4.1 | 7 | osimertinib 80 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:35:58.792664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495128 | REC_0007902 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10.3 | 69 | female | 0 | 11 | 5.9 | 1 | osimertinib 80 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:35:58.792895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250778 | REC_0007903 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 17.1 | 65 | female | 0 | 11 | 7 | 2 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:35:58.793132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350214 | REC_0007904 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 10.6 | 52 | male | 0 | 20 | 5.5 | 1 | alectinib 600 mg BID | 16.2 | false | MSS | 2026-03-15T05:35:58.793365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498756 | REC_0007905 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 12.3 | 72 | male | 2 | 23 | 5 | 9 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.793645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945580 | REC_0007906 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 16.2 | 66 | female | 0 | 17 | 8.2 | 4 | sotorasib 960 mg daily | 18 | false | MSI-H | 2026-03-15T05:35:58.793883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827016 | REC_0007907 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 8.8 | 56 | male | 0 | 22 | 6.5 | 2 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:58.794115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568135 | REC_0007908 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 8.9 | 79 | female | 2 | 3 | 3.9 | 1 | pembrolizumab 200 mg q3w | 18.7 | false | MSS | 2026-03-15T05:35:58.794345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753460 | REC_0007909 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.7 | 57 | female | 1 | 20 | 6 | 2 | osimertinib 80 mg daily | 19 | false | MSI-H | 2026-03-15T05:35:58.794582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190697 | REC_0007910 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.5 | 80 | male | 0 | 12 | 6.7 | 4 | entrectinib 600 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:58.794815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474822 | REC_0007911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.9 | 76 | female | 3 | 16 | 5.9 | 4 | osimertinib 80 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:58.795051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540928 | REC_0007912 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.1 | 51 | female | 0 | 16 | 6.4 | 8 | entrectinib 600 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:58.795283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997469 | REC_0007913 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 10 | 79 | female | 2 | 19 | 4.3 | 4 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:58.795515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160837 | REC_0007914 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.1 | 60 | male | 0 | 39 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:35:58.795743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282155 | REC_0007915 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 13.7 | 71 | female | 1 | 9 | 5 | 1 | alectinib 600 mg BID | 25.5 | true | MSS | 2026-03-15T05:35:58.795981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562702 | REC_0007916 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 16.6 | 58 | female | 0 | 13 | 5 | 1 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:58.796370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548354 | REC_0007917 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.9 | 53 | male | 0 | 24 | 3.8 | 1 | osimertinib 80 mg daily | 21.2 | true | MSI-H | 2026-03-15T05:35:58.796612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914852 | REC_0007918 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 17 | 3.8 | 69 | female | 1 | 19 | 5.2 | 0 | pembrolizumab 200 mg q3w | 40.9 | false | MSS | 2026-03-15T05:35:58.796895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214991 | REC_0007919 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 4.6 | 63 | female | 1 | 33 | 4.4 | 4 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:35:58.797131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692176 | REC_0007920 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 13.5 | 64 | female | 0 | 20 | 5.7 | 2 | sotorasib 960 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:35:58.797380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365459 | REC_0007921 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 10.9 | 77 | female | 1 | 11 | 5.1 | 8 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:35:58.797613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465134 | REC_0007922 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 6.5 | 70 | female | 2 | 16 | 6.5 | 5 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:58.797841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360182 | REC_0007923 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.4 | 76 | female | 3 | 8 | 7.4 | 6 | pembrolizumab 200 mg q3w | 9 | true | MSS | 2026-03-15T05:35:58.798068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664601 | REC_0007924 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.5 | 62 | male | 0 | 10 | 7.2 | 7 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:58.798302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210501 | REC_0007925 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.2 | 69 | female | 1 | 25 | 8.4 | 2 | entrectinib 600 mg daily | 22 | true | MSI-H | 2026-03-15T05:35:58.798535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827001 | REC_0007926 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.6 | 78 | female | 3 | 14 | 3.1 | 3 | sotorasib 960 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:58.798766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340404 | REC_0007927 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 10.1 | 87 | female | 1 | 23 | 3.7 | 2 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:35:58.798999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895795 | REC_0007928 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.6 | 69 | female | 0 | 20 | 7.4 | 7 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:58.799231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484469 | REC_0007929 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10.5 | 71 | male | 3 | 14 | 2 | 5 | pembrolizumab 200 mg q3w | 12.3 | false | MSI-H | 2026-03-15T05:35:58.799466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296077 | REC_0007930 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.8 | 52 | male | 0 | 10 | 6.3 | 2 | alectinib 600 mg BID | 18.5 | false | MSI-H | 2026-03-15T05:35:58.799699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553830 | REC_0007931 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.6 | 68 | male | 0 | 12 | 8 | 5 | pembrolizumab 200 mg q3w | 11.1 | true | MSI-H | 2026-03-15T05:35:58.799986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527951 | REC_0007932 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 19.6 | 78 | male | 2 | 11 | 6.2 | 6 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:58.800253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880067 | REC_0007933 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.3 | 70 | female | 1 | 12 | 6.9 | 4 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:58.800494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189485 | REC_0007934 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.1 | 70 | female | 1 | 11 | 5 | 1 | pembrolizumab 200 mg q3w | 22.4 | false | MSS | 2026-03-15T05:35:58.800723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741799 | REC_0007935 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 12.3 | 59 | male | 2 | 13 | 2.7 | 0 | alectinib 600 mg BID | 54.2 | true | MSS | 2026-03-15T05:35:58.800960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480452 | REC_0007936 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.8 | 64 | male | 1 | 11 | 4.8 | 1 | alectinib 600 mg BID | 13.9 | true | MSI-H | 2026-03-15T05:35:58.801196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432918 | REC_0007937 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 32 | 8.1 | 74 | female | 2 | 15 | 7.7 | 0 | osimertinib 80 mg daily | 21.1 | false | MSS | 2026-03-15T05:35:58.801425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355537 | REC_0007938 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 11.3 | 66 | male | 0 | 23 | 6.3 | 2 | entrectinib 600 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:58.801661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876879 | REC_0007939 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.2 | 70 | female | 1 | 20 | 6.8 | 6 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.801895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315361 | REC_0007940 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.1 | 78 | female | 2 | 15 | 4.8 | 6 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:58.802123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316056 | REC_0007941 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 72 | female | 2 | 9 | 6.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:58.802350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802873 | REC_0007942 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 12.1 | 56 | female | 0 | 25 | 5.2 | 1 | entrectinib 600 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:58.802587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459624 | REC_0007943 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.9 | 81 | female | 2 | 3 | 7 | 1 | osimertinib 80 mg daily | 18.8 | false | MSS | 2026-03-15T05:35:58.802820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507774 | REC_0007944 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.6 | 62 | female | 1 | 12 | 5.8 | 6 | sotorasib 960 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:58.803097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179720 | REC_0007945 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.9 | 75 | female | 2 | 50 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:35:58.803332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150045 | REC_0007946 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 17 | 74 | female | 2 | 15 | 5.1 | 6 | entrectinib 600 mg daily | 19.4 | true | MSI-H | 2026-03-15T05:35:58.803564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141252 | REC_0007947 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.2 | 72 | female | 2 | 16 | 2.9 | 6 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:58.803793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867449 | REC_0007948 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.6 | 59 | male | 0 | 16 | 6.2 | 6 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:35:58.804022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323144 | REC_0007949 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 10.2 | 53 | male | 0 | 31 | 7.3 | 6 | pembrolizumab 200 mg q3w | 12.7 | true | MSS | 2026-03-15T05:35:58.804282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333233 | REC_0007950 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 10.6 | 71 | female | 2 | 15 | 6.9 | 2 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:58.804516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301273 | REC_0007951 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.3 | 58 | female | 1 | 14 | 5 | 3 | entrectinib 600 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:58.804754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225781 | REC_0007952 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.5 | 72 | male | 2 | 49 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSS | 2026-03-15T05:35:58.804983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657866 | REC_0007953 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 10.7 | 57 | female | 0 | 16 | 6 | 0 | osimertinib 80 mg daily | 23.4 | true | MSS | 2026-03-15T05:35:58.805219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257620 | REC_0007954 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.6 | 69 | female | 0 | 55 | 4.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:58.805445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332541 | REC_0007955 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.3 | 69 | female | 0 | 1 | 7.3 | 5 | pembrolizumab 200 mg q3w | 19.7 | true | MSS | 2026-03-15T05:35:58.805675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583594 | REC_0007956 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 7.2 | 72 | female | 3 | 74 | 7.3 | 1 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:58.805908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990039 | REC_0007957 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 16.2 | 68 | female | 1 | 4 | 5.8 | 7 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:58.806185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962105 | REC_0007958 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 11.1 | 60 | female | 1 | 17 | 6.2 | 2 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.806423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112831 | REC_0007959 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12 | 64 | female | 1 | 12 | 7.8 | 2 | sotorasib 960 mg daily | 20.7 | true | MSS | 2026-03-15T05:35:58.806662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267234 | REC_0007960 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 10.1 | 70 | female | 1 | 12 | 6.2 | 2 | sotorasib 960 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:58.806897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855037 | REC_0007961 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.4 | 68 | female | 1 | 7 | 5.7 | 7 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:58.807126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228726 | REC_0007962 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 7.3 | 62 | male | 0 | 19 | 5.5 | 7 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.807359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361366 | REC_0007963 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.1 | 59 | female | 0 | 43 | 2.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.3 | true | MSS | 2026-03-15T05:35:58.807593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235248 | REC_0007964 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 17.6 | 76 | female | 2 | 15 | 6.3 | 5 | alectinib 600 mg BID | 6.3 | false | MSS | 2026-03-15T05:35:58.807830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590366 | REC_0007965 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15.6 | 71 | female | 3 | 15 | 6.8 | 4 | alectinib 600 mg BID | 5.5 | false | MSI-H | 2026-03-15T05:35:58.808068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312366 | REC_0007966 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.7 | 65 | female | 1 | 41 | 4.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:58.808496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677304 | REC_0007967 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.6 | 74 | female | 2 | 8 | 2.4 | 2 | osimertinib 80 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:58.808751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352385 | REC_0007968 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 8.9 | 69 | female | 1 | 11 | 4.7 | 5 | entrectinib 600 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:58.808989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892218 | REC_0007969 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.7 | 63 | male | 1 | 24 | 4.7 | 6 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:58.809231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494256 | REC_0007970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.8 | 52 | female | 0 | 0 | 5.5 | 2 | osimertinib 80 mg daily | 23.7 | true | MSS | 2026-03-15T05:35:58.809592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147265 | REC_0007971 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 6.8 | 51 | female | 0 | 16 | 4.6 | 1 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:58.809838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534217 | REC_0007972 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.5 | 73 | female | 1 | 13 | 3.7 | 5 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:35:58.810085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871567 | REC_0007973 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.9 | 76 | male | 1 | 24 | 3.7 | 7 | alectinib 600 mg BID | 9.8 | false | MSI-H | 2026-03-15T05:35:58.810334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502493 | REC_0007974 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 9.3 | 64 | male | 0 | 20 | 4 | 3 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:58.810573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641910 | REC_0007975 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 5.7 | 50 | male | 0 | 27 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:58.810813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452759 | REC_0007976 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.8 | 67 | female | 1 | 10 | 5.2 | 5 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:35:58.811045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849525 | REC_0007977 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.4 | 54 | male | 0 | 16 | 5.6 | 8 | pembrolizumab 200 mg q3w | 10.9 | true | MSS | 2026-03-15T05:35:58.811281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511643 | REC_0007978 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.3 | 71 | male | 1 | 15 | 5.5 | 6 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:58.811534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965652 | REC_0007979 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11 | 66 | male | 1 | 17 | 7 | 6 | alectinib 600 mg BID | 14.3 | false | MSS | 2026-03-15T05:35:58.811784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931350 | REC_0007980 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4 | 57 | male | 0 | 79 | 6.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:58.812034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450011 | REC_0007981 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.9 | 55 | female | 0 | 14 | 6.6 | 7 | alectinib 600 mg BID | 13.9 | true | MSS | 2026-03-15T05:35:58.812362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956101 | REC_0007982 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.5 | 68 | female | 1 | 59 | 4 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:35:58.812624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673947 | REC_0007983 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 14.9 | 54 | female | 0 | 10 | 6.3 | 1 | sotorasib 960 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:58.813030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378259 | REC_0007984 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 7.7 | 62 | female | 1 | 17 | 6.1 | 2 | alectinib 600 mg BID | 16.9 | false | MSS | 2026-03-15T05:35:58.813295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435477 | REC_0007985 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 9.5 | 69 | female | 1 | 7 | 5.1 | 0 | alectinib 600 mg BID | 19.9 | false | MSS | 2026-03-15T05:35:58.813544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339800 | REC_0007986 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 9.5 | 69 | female | 1 | 7 | 5 | 2 | alectinib 600 mg BID | 18.8 | false | MSS | 2026-03-15T05:35:58.813785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673079 | REC_0007987 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 7.9 | 64 | male | 0 | 12 | 6 | 2 | sotorasib 960 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:58.814027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402531 | REC_0007988 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.4 | 62 | female | 1 | 39 | 7.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.8 | true | MSS | 2026-03-15T05:35:58.814274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883226 | REC_0007989 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 15.7 | 55 | female | 0 | 19 | 6.1 | 4 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:35:58.814529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313861 | REC_0007990 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.6 | 84 | female | 1 | 56 | 3.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:35:58.814779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677244 | REC_0007991 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.7 | 68 | female | 1 | 43 | 7.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:35:58.815024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858929 | REC_0007992 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.4 | 69 | female | 0 | 10 | 4.1 | 7 | entrectinib 600 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:58.815273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779664 | REC_0007993 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 4 | 70 | female | 1 | 41 | 3.4 | 4 | pembrolizumab 200 mg q3w | 10 | true | MSS | 2026-03-15T05:35:58.815522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343056 | REC_0007994 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 6.3 | 74 | female | 2 | 14 | 6.1 | 2 | pembrolizumab 200 mg q3w | 32.3 | true | MSS | 2026-03-15T05:35:58.815768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845051 | REC_0007995 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13 | 76 | female | 2 | 17 | 3.4 | 5 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:58.816021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213917 | REC_0007996 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.6 | 55 | male | 1 | 20 | 6.3 | 10 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:35:58.816500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323214 | REC_0007997 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 5.5 | 64 | male | 0 | 5 | 5.6 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.816777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202653 | REC_0007998 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.6 | 74 | female | 2 | 10 | 7.9 | 5 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:58.817038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706590 | REC_0007999 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 9 | 76 | female | 0 | 6 | 7.4 | 1 | sotorasib 960 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.817288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860061 | REC_0008000 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11 | 59 | female | 0 | 17 | 7 | 2 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:35:58.817536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.